DK3494133T3 - Anti-kras-g12d-t-cellereceptorer - Google Patents

Anti-kras-g12d-t-cellereceptorer Download PDF

Info

Publication number
DK3494133T3
DK3494133T3 DK17749580.1T DK17749580T DK3494133T3 DK 3494133 T3 DK3494133 T3 DK 3494133T3 DK 17749580 T DK17749580 T DK 17749580T DK 3494133 T3 DK3494133 T3 DK 3494133T3
Authority
DK
Denmark
Prior art keywords
kras
cell receptors
receptors
cell
Prior art date
Application number
DK17749580.1T
Other languages
Danish (da)
English (en)
Inventor
Eric Tran
Yong-Chen Lu
Paul F Robbins
Steven A Rosenberg
Zhili Zheng
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK3494133T3 publication Critical patent/DK3494133T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
DK17749580.1T 2016-08-02 2017-07-31 Anti-kras-g12d-t-cellereceptorer DK3494133T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Publications (1)

Publication Number Publication Date
DK3494133T3 true DK3494133T3 (da) 2022-09-19

Family

ID=59564253

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17749580.1T DK3494133T3 (da) 2016-08-02 2017-07-31 Anti-kras-g12d-t-cellereceptorer

Country Status (20)

Country Link
US (6) US10611816B2 (enExample)
EP (2) EP3494133B1 (enExample)
JP (4) JP6993402B2 (enExample)
KR (1) KR102527052B1 (enExample)
CN (2) CN118063591A (enExample)
AU (2) AU2017306038B2 (enExample)
CA (1) CA3032870A1 (enExample)
DK (1) DK3494133T3 (enExample)
ES (1) ES2928051T3 (enExample)
HR (1) HRP20221183T1 (enExample)
HU (1) HUE060121T2 (enExample)
IL (2) IL301894B2 (enExample)
LT (1) LT3494133T (enExample)
PL (1) PL3494133T3 (enExample)
PT (1) PT3494133T (enExample)
RS (1) RS63615B1 (enExample)
SG (2) SG11201900654QA (enExample)
SI (1) SI3494133T1 (enExample)
SM (1) SMT202200379T1 (enExample)
WO (1) WO2018026691A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3494133T (lt) * 2016-08-02 2022-12-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t ląstelės receptoriai
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
SG11202002425PA (en) 2017-09-20 2020-04-29 The United States Of America As Represented By The Secretary Hla class ii-restricted t cell receptors against mutated ras
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
US20220088190A1 (en) * 2019-01-25 2022-03-24 The Trustees Of The University Of Pennsylvania Compositions and Methods for Targeting Mutant RAS
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
US20220409711A1 (en) * 2019-11-05 2022-12-29 Board Of Regents, The University Of Texas System Hla restricted hormad1 t cell receptors and uses thereof
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021135178A1 (zh) * 2019-12-30 2021-07-08 华夏英泰(北京)生物技术有限公司 一种增强型t细胞受体star及其应用
US20230272038A1 (en) * 2020-07-13 2023-08-31 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12d mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
JP2023551204A (ja) * 2020-11-20 2023-12-07 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
JP2023551819A (ja) * 2020-11-25 2023-12-13 ジーニアス・バイオテクノロジー・インコーポレイテッド 抗原特異的t細胞並びにその作製及び使用方法
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
JP2025524005A (ja) * 2022-07-22 2025-07-25 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 養子免疫療法のための亢進された機能を有するcd3発現ナチュラルキラー細胞
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
CN120693174A (zh) * 2022-12-13 2025-09-23 百欧恩泰美国公司 T细胞受体构建体及其用途
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
WO2008089053A2 (en) 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2618835B1 (en) 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
EP2749642A4 (en) * 2011-11-30 2015-03-04 Nat Cancer Ct INDUCED MALIGNE STEM CELLS
KR20160013049A (ko) * 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
PL3223850T3 (pl) 2014-11-26 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko zmutowanemu kras
EP3901169A1 (en) 2015-09-15 2021-10-27 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
LT3494133T (lt) * 2016-08-02 2022-12-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t ląstelės receptoriai
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Also Published As

Publication number Publication date
US20190177395A1 (en) 2019-06-13
ES2928051T3 (es) 2022-11-15
JP2019527555A (ja) 2019-10-03
LT3494133T (lt) 2022-12-12
US20210300988A1 (en) 2021-09-30
US11208456B2 (en) 2021-12-28
HUE060121T2 (hu) 2023-01-28
AU2017306038A1 (en) 2019-02-14
JP7413338B2 (ja) 2024-01-15
JP2024045139A (ja) 2024-04-02
EP4159751A1 (en) 2023-04-05
KR20190064566A (ko) 2019-06-10
CN109790211A (zh) 2019-05-21
US20250340611A1 (en) 2025-11-06
IL301894A (en) 2023-06-01
EP3494133B1 (en) 2022-07-06
CN118063591A (zh) 2024-05-24
AU2023233125A1 (en) 2023-10-12
SG11201900654QA (en) 2019-02-27
JP2025090690A (ja) 2025-06-17
WO2018026691A1 (en) 2018-02-08
JP7649370B2 (ja) 2025-03-19
JP6993402B2 (ja) 2022-02-03
PL3494133T3 (pl) 2022-11-21
SMT202200379T1 (it) 2022-11-18
RS63615B1 (sr) 2022-10-31
IL264425B1 (en) 2023-05-01
US20200247869A1 (en) 2020-08-06
US10611816B2 (en) 2020-04-07
CN109790211B (zh) 2024-03-26
SG10201913959WA (en) 2020-03-30
US12391742B2 (en) 2025-08-19
IL301894B1 (en) 2024-10-01
IL264425B2 (en) 2023-09-01
PT3494133T (pt) 2022-09-28
EP3494133A1 (en) 2019-06-12
US11897933B2 (en) 2024-02-13
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
HRP20221183T1 (hr) 2022-12-09
US20240209059A1 (en) 2024-06-27
IL301894B2 (en) 2025-02-01
SI3494133T1 (sl) 2022-11-30
IL264425A (enExample) 2019-03-31
JP2022050400A (ja) 2022-03-30
KR102527052B1 (ko) 2023-04-27
US20220089677A1 (en) 2022-03-24
US11840561B2 (en) 2023-12-12
AU2023233125B2 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
DK3440105T3 (da) T-cellereceptorer
DK3440106T3 (da) T-cellereceptorer
DK3494133T3 (da) Anti-kras-g12d-t-cellereceptorer
IL262124A (en) T cell receptors
IL262146A (en) T cell receptors
DK3305266T3 (da) Stiftformig stimulationsindretning
PT3223850T (pt) Receptores de células t anti-kras mutado
EP4015404C0 (en) STRAPPING DEVICE
DK3448882T3 (da) Anti-kk-lc-1-t-cellereceptorer
DK3394094T3 (da) T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset
DK3404169T3 (da) Gondolanordning
EP3472208C0 (en) T cell receptors and uses thereof
DK3126381T4 (da) Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK4011339T3 (da) Stomianordning
DE112016005396A5 (de) Anschlusseinrichtung
DK3426850T3 (da) Kabellægnings-indretning
EP3435660A4 (en) HEAD-MOUNTED DISPLAY
EP3529267C0 (en) T CELL RECEPTOR
DK3290073T3 (da) Forbindelsesanordning
EP3695822A4 (en) PROCESS ASSISTANCE DEVICE
LT3433270T (lt) T ląstelių receptoriai
EP3521179A4 (en) POINTING MECHANISM
EP3551657A4 (en) CHIMERIC CHLOROTOXIN RECEPTORS
EP3453648C0 (de) Zulaufvorrichtung
DK3516155T3 (da) Forbindelsesanordning